NCT03232567Phase 2Completed

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2018-03-07Actual

Enrollment · participants60Actual

Source updated2024-04-30Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Influenza

Treatments or interventions studied

NasoVAXBiological

Primary outcomes · main study measures

Read the study measures

measure: Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability]; description: Adverse events (AEs): counts and percentages of subjects with AEs Day 1 to day 29 and Medically attended AEs (MAEs), serious AEs (SAEs), new-onset chronic illnesses (NCIs) from Day 1 to Day 181; timeFrame: Day 1 to Day 181; measure: Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability]; description: Reactogenicity: counts and percentages of subjects with 'yes' to any reactogenicity event (nasal irritation, sneezing, nasal congestion, sore throat, change in smell, change in taste, change in vision, eye pain, headache, fatigue, muscle ache, nausea, vomiting, diarrhea, chills, fever); timeFrame: 14-days after vaccination

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history